2 soaring growth stocks I’d consider buying today

These two stocks have grown strongly in recent years and Harvey Jones expects further progress.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Drug developer Indivior (LSE: INDV) was set up in 1994 to pioneer treatments for opioid dependence and three years after floating now boasts a market cap of £2.9bn. However, it suffered a major blow at the end of August, its share price crashing 40% after the District Court of Delaware allowed the marketing of Dr Reddy’s, a rival, generic version of Indivior’s Suboxone film treatment for opioid addiction that generates 80% of its revenues.

Bitter pill

Indivior has since recovered and remains a great growth stock for shrewd investors. At 400p its share price is only 4% below its pre-crash level, as investors decided the damage may not be so severe after all. As well as the pill, the group also offers patient management, and is working on new projects and building relationships to hang onto its market share and diversify from its main product. All is not lost.

Today the company published its nine-month financial results and full-year guidance, with the share price up 0.65% in consequence. There are positives in there, with net revenue up 4% to $828m year-to-date, as strong US market growth offset generic competition. Operating profit jumped from $78m to $308m on higher net revenues and lower R&D and legal expenses, with adjusted operating profit up 6% to $333m. The company’s net cash now stands at $322m, up from $131 in full-year 2016.

News dependent

Indivior is appealing the Delaware ruling on its generic rival so investors must allow for the uncertainty surrounding the outcome. The other development to watch is its promising pipeline, following its successful NDA submission of RBP-7000 in schizophrenia and the endorsement of the FDA’s Psychopharmacologic Drugs Advisory and Drug Safety and Risk Management Advisory Committees for RBP-6000.This is the group’s “potentially transformational” product for the treatment of opioid use disorder.

Today’s forecast valuation of 11.4 times earnings reflects the uncertainty, with City analysts expecting earnings and revenue volatility going forward. The share price stands 95% higher than two years ago and it remains tempting, but only if you understand all the risks.

Keep informed

Business media giant Informa (LSE: INF) has also enjoyed a strong growth spurt, its share price up 85% over five years and 32% over two. Recent half-yearly results showed pre-tax profits rising 50% to £148.8m with revenues up 41.3% due to strong trading in its global exhibitions division. It is nice to see somebody making money from publishing, aside from Facebook.

Global exhibitions now make up 37.4% of the group’s total revenue after rising an impressive 77.7% to £342.8m. There was good news for income investors as well with the interim dividend increase 6.2% to 6.65p. The yield is still a relatively lowly 2.79% but the board is showing progression on this front. 

Solid growth

I have just been reading this £5.9bn FTSE 100 firm’s earnings per share (EPS) growth history and I have rarely seen one more consistent, with five consecutive years of low-single-digit growth. Markets are forecasting more action with 10% growth in 2017 and 7% in 2018.

The forecast yield is 3%, handily covered 2.3 times. Today you can buy Informa at a fair 14.8 times earnings, which suggests that this growth stock could be a bargain. It may not promise spectacular returns, but it looks extremely solid.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mixed-race female couple enjoying themselves on a walk
Investing Articles

A once-in-a-decade chance to get rich buying growth stocks?

We haven't seen a good spell for growth stocks for quite a few years now. But I reckon the signs…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

The FTSE 100 is full of bargains! Here’s 1 stock I’m eyeing up

A weak economic outlook has hurt the FTSE 100. This Fool explains why she likes the look of this consumer…

Read more »

Investing Articles

2 no-brainer beginner FTSE 100 stocks to buy for my portfolio

Getting started with investing can be daunting. Here are two stocks for beginners to consider buying to build their first…

Read more »

Young black man looking at phone while on the London Overground
Investing Articles

2 recession-resistant UK shares investors should consider buying

Our writer details two UK shares she feels could withstand some of the ill-effects of the current malaise to provide…

Read more »

Tanker coming in to dock in calm waters and a clear sunset
Investing Articles

Glencore share price drops on results. Time to buy?

The Glencore share price wobbled a bit after a weak set of 2023 results. Here's why I have the stock…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

Big trouble in China sinks HSBC shares. Should I invest after record FY results?

HSBC shares have slumped following a disappointing end to 2023 for the FTSE stock. Royston Wild explains why this may…

Read more »

View of Tower Bridge in Autumn
Investing Articles

3 dirt cheap FTSE 100 shares to snap up today?

The FTSE 100 is rallying, but many shares still look super cheap on fundamentals. Is our writer buying these three…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

FTSE 100 earnings: what can we expect from Rolls-Royce in 2024?

The Rolls-Royce share price tripled in 2023. Roland Head wonders whether this FTSE 100 stock could continue that impressive trajectory…

Read more »